Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical obtained clinical trial approval for the TQF6422 injection from China's National Medical Products Administration.
The drug will be tested for weight management in adult patients with obesity, or in overweight adults with at least one weight-related comorbidity.